| Biomarker ID | 1214 |
| PMID | 24080222 |
| Year | 2013 |
| Biomarker | PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Proteins Involved in Prostate Cancer |
| Experiment | Prostate Cancer Vs Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 71 consecutive patients with clinically suspected PCa were included in the study. 68 had PCa and 95 did not. |
| Senstivity | 0.68 (95% CI: 0.57-0.79) |
| Specificity | 0.66 (95% CI: 0.57-0.76) |
| AUC | 0.67 (95% CI: 0.60-0.74) |
| Accuracy | 0.67 (95% CI: 0.60-0.74) |
| Level Of Significance | NA |
| Method Used | NA |
| Clinical | No |
| Remarks | Results (Accuracy, Sensitivity, Specificity, AUC) shown for PCA3 ≥ 44 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |